PubRank

Graham Casey

Author PubWeight™ 168.87‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Retracted Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2006 10.08
2 Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 2006 4.34
3 Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005 3.99
4 Principles for the post-GWAS functional characterization of cancer risk loci. Nat Genet 2011 3.73
5 Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet 2012 3.19
6 The landscape of recombination in African Americans. Nature 2011 3.06
7 Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet 2011 2.70
8 Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. Gastroenterology 2012 2.57
9 CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res 2013 2.57
10 Prevalence of alterations in DNA mismatch repair genes in patients with young-onset colorectal cancer. Clin Gastroenterol Hepatol 2010 2.50
11 Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer. PLoS Genet 2011 2.47
12 Meta-analysis of new genome-wide association studies of colorectal cancer risk. Hum Genet 2011 2.35
13 Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006 2.23
14 Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 2012 2.22
15 Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev 2008 2.12
16 Variants on 9p24 and 8q24 are associated with risk of colorectal cancer: results from the Colon Cancer Family Registry. Cancer Res 2007 2.02
17 SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci U S A 2003 2.01
18 Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates. Cancer Res 2003 1.95
19 Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity. Cancer Res 2005 1.92
20 Genome-wide association analyses in East Asians identify new susceptibility loci for colorectal cancer. Nat Genet 2012 1.85
21 A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet 2013 1.82
22 8q24 and prostate cancer: association with advanced disease and meta-analysis. Eur J Hum Genet 2008 1.72
23 Associations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomarkers Prev 2009 1.72
24 The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat 2008 1.68
25 Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer 2006 1.62
26 Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev 2010 1.62
27 Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat 2013 1.55
28 Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet 2011 1.54
29 Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha. Am J Epidemiol 2006 1.53
30 Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Cancer Res 2007 1.52
31 Cumulative impact of common genetic variants and other risk factors on colorectal cancer risk in 42,103 individuals. Gut 2012 1.52
32 The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin. Oncogene 2005 1.50
33 Identification, replication, and fine-mapping of Loci associated with adult height in individuals of african ancestry. PLoS Genet 2011 1.47
34 Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients. Clin Cancer Res 2006 1.45
35 Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007 1.45
36 A common 8q24 variant and the risk of colon cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2008 1.42
37 Genotype-environment interactions in microsatellite stable/microsatellite instability-low colorectal cancer: results from a genome-wide association study. Cancer Epidemiol Biomarkers Prev 2011 1.40
38 Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Mol Cancer 2007 1.40
39 Fine-mapping of colorectal cancer susceptibility loci at 8q23.3, 16q22.1 and 19q13.11: refinement of association signals and use of in silico analysis to suggest functional variation and unexpected candidate target genes. Hum Mol Genet 2011 1.33
40 Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk. Clin Cancer Res 2008 1.31
41 Breast cancer metastasis suppressor-1 differentially modulates growth factor signaling. J Biol Chem 2008 1.30
42 Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer. J Clin Oncol 2007 1.30
43 Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis 2006 1.30
44 Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors results from the Colon Cancer Family Registry. J Mol Diagn 2011 1.27
45 Identification of metastasis-associated proteins through protein analysis of metastatic MDA-MB-435 and metastasis-suppressed BRMS1 transfected-MDA-MB-435 cells. Clin Exp Metastasis 2004 1.22
46 Genome-wide scan of brothers: replication and fine mapping of prostate cancer susceptibility and aggressiveness loci. Prostate 2003 1.22
47 DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2004 1.19
48 Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer. J Mol Diagn 2008 1.17
49 cis-Expression QTL analysis of established colorectal cancer risk variants in colon tumors and adjacent normal tissue. PLoS One 2012 1.14
50 Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clin Cancer Res 2009 1.13
51 Prostate cancer aggressiveness locus on chromosome 7q32-q33 identified by linkage and allelic imbalance studies. Neoplasia 2002 1.11
52 Reduced expression of autotaxin predicts survival in uveal melanoma. Br J Ophthalmol 2007 1.10
53 Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev 2005 1.09
54 Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer. BMC Cancer 2009 1.07
55 Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control 2003 1.07
56 Refinement of the associations between risk of colorectal cancer and polymorphisms on chromosomes 1q41 and 12q13.13. Hum Mol Genet 2011 1.07
57 Association of common genetic variants in SMAD7 and risk of colon cancer. Carcinogenesis 2009 1.06
58 Methodological Issues in Multistage Genome-wide Association Studies. Stat Sci 2009 1.06
59 Prostate cancer susceptibility variants confer increased risk of disease progression. Cancer Epidemiol Biomarkers Prev 2010 1.06
60 Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas. Dis Colon Rectum 2009 1.06
61 Association of vitamin D receptor gene variants, adiposity and colon cancer. Carcinogenesis 2008 1.05
62 Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1. Int J Cancer 2008 1.04
63 Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. J Mol Diagn 2010 1.04
64 A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age. Cancer Epidemiol Biomarkers Prev 2014 1.03
65 BRMS1 contributes to the negative regulation of uPA gene expression through recruitment of HDAC1 to the NF-kappaB binding site of the uPA promoter. Clin Exp Metastasis 2009 1.02
66 Association of the innate immunity and inflammation pathway with advanced prostate cancer risk. PLoS One 2012 1.01
67 Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers. Oncogene 2002 1.00
68 Deciphering the genetic architecture of low-penetrance susceptibility to colorectal cancer. Hum Mol Genet 2013 1.00
69 Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens. Mod Pathol 2004 1.00
70 HOXB13 mutation and prostate cancer: studies of siblings and aggressive disease. Cancer Epidemiol Biomarkers Prev 2013 1.00
71 Genetic susceptibility and oxidative stress in prostate cancer: integrated model with implications for prevention. Urology 2006 1.00
72 Comparison of the clinical prediction model PREMM(1,2,6) and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer. Gut 2012 0.99
73 Polymorphisms in polycyclic aromatic hydrocarbon metabolism and conjugation genes, interactions with smoking and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2006 0.99
74 Incorporating prior biologic information for high-dimensional rare variant association studies. Hum Hered 2013 0.98
75 Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate 2004 0.98
76 A pooled analysis of smoking and colorectal cancer: timing of exposure and interactions with environmental factors. Cancer Epidemiol Biomarkers Prev 2012 0.97
77 Copy number alterations in prostate tumors and disease aggressiveness. Genes Chromosomes Cancer 2011 0.97
78 Confirmation of linkage to and localization of familial colon cancer risk haplotype on chromosome 9q22. Cancer Res 2010 0.96
79 CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003 0.96
80 Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer 2014 0.96
81 Genome-wide search for gene-gene interactions in colorectal cancer. PLoS One 2012 0.96
82 Characterization of the human polymeric immunoglobulin receptor (PIGR) 3'UTR and differential expression of PIGR mRNA during colon tumorigenesis. J Biomed Sci 2003 0.95
83 Interleukin-22 genetic polymorphisms and risk of colon cancer. Cancer Causes Control 2010 0.95
84 Integrated analysis of genome-wide copy number alterations and gene expression in microsatellite stable, CpG island methylator phenotype-negative colon cancer. Genes Chromosomes Cancer 2013 0.94
85 Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk. Carcinogenesis 2006 0.94
86 Identification and characterization of functional risk variants for colorectal cancer mapping to chromosome 11q23.1. Hum Mol Genet 2013 0.93
87 Colorectal cancer linkage on chromosomes 4q21, 8q13, 12q24, and 15q22. PLoS One 2012 0.93
88 FTO polymorphisms are associated with adult body mass index (BMI) and colorectal adenomas in African-Americans. Carcinogenesis 2011 0.92
89 Pleiotropic effects of genetic risk variants for other cancers on colorectal cancer risk: PAGE, GECCO and CCFR consortia. Gut 2013 0.92
90 Fine-mapping of genome-wide association study-identified risk loci for colorectal cancer in African Americans. Hum Mol Genet 2013 0.92
91 Vitamin D receptor genotypes/haplotypes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2006 0.92
92 The association of tumor microsatellite instability phenotype with family history of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009 0.91
93 Meta-analysis of 8q24 for seven cancers reveals a locus between NOV and ENPP2 associated with cancer development. BMC Med Genet 2011 0.90
94 Fluorescence in situ hybridization of cytologic specimens from Barrett's esophagus: a pilot feasibility study. Gastrointest Endosc 2004 0.89
95 Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2. Eur J Hum Genet 2004 0.89
96 No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. World J Gastroenterol 2009 0.89
97 No association between genetic polymorphisms in IGF-I and IGFBP-3 and prostate cancer. Cancer Epidemiol Biomarkers Prev 2004 0.89
98 Role of IKK and oscillatory NFkappaB kinetics in MMP-9 gene expression and chemoresistance to 5-fluorouracil in RKO colorectal cancer cells. Mol Carcinog 2007 0.88
99 Prostate cancer aggressiveness locus on chromosome segment 19q12-q13.1 identified by linkage and allelic imbalance studies. Genes Chromosomes Cancer 2003 0.88
100 Identification of novel variants in colorectal cancer families by high-throughput exome sequencing. Cancer Epidemiol Biomarkers Prev 2013 0.88
101 Ascending the learning curve--MSI testing experience of a six-laboratory consortium. Cancer Biomark 2006 0.87
102 Performance of PREMM(1,2,6), MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases. Genet Med 2012 0.87
103 Comparison of techniques for the successful detection of BRCA1 mutations in fixed paraffin-embedded tissue. Cancer Epidemiol Biomarkers Prev 2002 0.86
104 ADAMTSL3/punctin-2, a gene frequently mutated in colorectal tumors, is widely expressed in normal and malignant epithelial cells, vascular endothelial cells and other cell types, and its mRNA is reduced in colon cancer. Int J Cancer 2007 0.86
105 Pathological aggressiveness of prostatic carcinomas related to RNASEL R462Q allelic variants. J Urol 2008 0.85
106 Genetic predictors of circulating 25-hydroxyvitamin d and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2013 0.84
107 Identification of the methylator (serrated) colorectal cancer phenotype through precursor serrated polyps. Dis Colon Rectum 2009 0.84
108 MIC1 and IL1RN genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007 0.84
109 Relationship between methylenetetrahydrofolate reductase C677T and A1298C genotypes and haplotypes and prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev 2004 0.83
110 Meta-analysis of mismatch repair polymorphisms within the cogent consortium for colorectal cancer susceptibility. PLoS One 2013 0.82
111 Genetic risk factors for orofacial clefts in Central Africans and Southeast Asians. Am J Med Genet A 2014 0.82
112 No association between genetic polymorphisms in insulin and insulin receptor substrate-1 and prostate cancer. Cancer Epidemiol Biomarkers Prev 2005 0.81
113 Genetic variation in the inflammation and innate immunity pathways and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2013 0.81
114 Trans-fatty acid intake and increased risk of advanced prostate cancer: modification by RNASEL R462Q variant. Carcinogenesis 2007 0.81
115 No association between a tetranucleotide repeat polymorphism of CYP19 and prostate cancer. Cancer Epidemiol Biomarkers Prev 2004 0.80
116 Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history. Prostate 2007 0.79
117 Chromosomal autonomy of hMLH1 methylation in colon cancer. Oncogene 2002 0.78
118 Fine-mapping of prostate cancer aggressiveness loci on chromosome 7q22-35. Prostate 2010 0.78
119 No association between phosphatase and tensin homolog genetic polymorphisms and colon cancer. World J Gastroenterol 2009 0.77
120 Diffuse large B-cell lymphoma of the stomach: assessment of microsatellite instability, allelic imbalance, and trisomy of chromosomes 3, 12, and 18. Diagn Mol Pathol 2002 0.77
121 Association of testis derived transcript gene variants and prostate cancer risk. J Urol 2007 0.76
122 Erratum: A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer. Sci Rep 2015 0.76
123 Corrigendum: Genome-wide association study of colorectal cancer identifies six new susceptibility loci. Nat Commun 2015 0.76
124 Relationship between body size and prostate cancer in a sibling based case-control study. J Urol 2005 0.76
125 Non-Steroidal Anti-Inflammatory Drugs, Variation in Inflammatory Genes, and Aggressive Prostate Cancer. Pharmaceuticals (Basel) 2010 0.75
126 Reconstitution of TGF-beta sensitivity in the VACO-411 human colon carcinoma line by somatic cell fusion with MCF-7. J Biomed Sci 2003 0.75
127 Novel enhanced lung-colonizing variant of murine MBT-2 bladder cancer cells. Urology 2005 0.75